This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Gilead Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $22.606. Gilead Sciences's 10-Year median PS Ratio is 3.5844. Therefore, the Median PS Value for today is $81.03.
As of today (2024-12-12), Gilead Sciences's share price is $89.71. Gilead Sciences's Median PS Value is $81.03. Therefore, Gilead Sciences's Price to Median PS Value for today is 1.11.
The historical rank and industry rank for Gilead Sciences's Median PS Value or its related term are showing as below:
XSGO:GILD'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.46 Med: 0.79 Max: 1.11
Current: 1.11
During the past 13 years, the highest Price to Median PS Value of Gilead Sciences was 1.11. The lowest was 0.46. And the median was 0.79.
XSGO:GILD's Price-to-Median-PS-Value is ranked worse than 65.58% of 523
companies
in the Drug Manufacturers industry
Industry Median: 0.91
vs XSGO:GILD: 1.11
Gilead Sciences Median PS Value Historical Data
The historical data trend for Gilead Sciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gilead Sciences's Median PS Value
For the Drug Manufacturers - General subindustry, Gilead Sciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Price-to-Median-PS-Value falls into.
Gilead Sciences Median PS Value Calculation
Gilead Sciences's Median PS Value for today is calculated as
10-Year Median PS Ratio is 3.5844.
Gilead Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.606.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (XSGO:GILD) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Gilead Sciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
89.71
/
81.03
=
1.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences Median PS Value Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSGO:GILD has been successfully added to your 